TABLE 2.
Model 1 | CD25 | PD25 | ||||
---|---|---|---|---|---|---|
|
|
|||||
Estimate | P | R2 | Estimate | P | R2 | |
BP status | 0.26 | 0.001 | −0.20 | 0.007 | ||
| ||||||
Sex | 0.16 | 0.044 | 0.27 | 0.001 | ||
| ||||||
Race | 0.14 | 0.065 | 0.10 | −0.24 | 0.001 | 0.17 |
| ||||||
Model 2 | ||||||
BP status | 0.15 | 0.054 | −0.21 | 0.009 | ||
Sex | 0.20 | 0.010 | 0.27 | 0.001 | ||
Race | 0.11 | 0.159 | −0.24 | 0.001 | ||
Age | 0.14 | 0.071 | −0.04 | 0.574 | ||
BMI | 0.23 | 0.003 | 0.16 | 0.06 | 0.436 | 0.16 |
Note: Body size (BSA) was unrelated to both CD25 and PD25 in these models. For BP status 1 = high, 2 =normal; sex 1 =male, 2 =female; race 1 =African-American, 2 =white. CD25, dose of isoproterenol to increase heart rate by 25 bpm; PD25, dose of phenylephrine to increase mean arterial pressure by 25 mmHg.